Silva Gustavo S, Yeske Paul, Morrison Robert B, Linhares Daniel C L
Veterinary Diagnostic and Production Animal Medicine Department, Iowa State University, Ames, IA, USA.
Swine Vet Center P.A., St. Peter, MN, USA.
Prev Vet Med. 2019 Jul 1;168:95-102. doi: 10.1016/j.prevetmed.2019.04.008. Epub 2019 Apr 18.
Mycoplasma hyopneumoniae (Mhyo) is generally accepted to be the most common porcine respiratory pathogen worldwide causing big economical losses in swine production by affecting pig's downstream performance. The objective of this study was to develop a partial budget model to determine the payback period and economic value of two Mhyo elimination protocols. Retrospective data recorded from 2004 to 2017 from 70 breeding herds that implemented herd closure or whole-herd medication protocol targeting Mhyo elimination. Close out data was used to estimate differences in downstream performance between Mhyo-negative and positive flows. Assuming a 5000 sows breed-to-finish operation producing 135,870 weaned pigs and 125,000 finishing pigs/year, the total cost for implementing Mhyo elimination was $112,100 using the herd closure protocol, and $185,700 for the medication protocol. Statistically differences (p < 0.05) in downstream performance were observed for ADG and mortality, but not for feed conversion rate. The parameters that accounts for the greatest benefits were related to the improvement in ADG, savings in antibiotic medication in growing pigs and improvement in feed conversion rate. The benefit of Mhyo elimination was $877,375 per farm per year, or $7.00 per pig marketed. The estimated project value after 1 year was $616,121 for the herd closure considering a probability of success of 83%, and $323,177 for the medication protocol for 58% chance of success. The project value reached the break-even point when the cost per sow was $145.64 for the herd closure and $101.78 for the medication protocol. The payback period was 2 months after the start of marketing Mhyo-negative pigs for the herd closure, and 7 months for the medication protocol adjusted for the probability of success for each protocol. The protocols described here can be easily applied with a good success rate and showing that the benefits obtained are greater than the costs of project failure. Even if the farm stayed negative only a year, the economic benefits downstream are worth the investment. This information may help producers and veterinarians on decision-making process to conduct a Mhyo elimination protocol in their herds.
猪肺炎支原体(Mhyo)被普遍认为是全球最常见的猪呼吸道病原体,它通过影响猪的下游生产性能,给养猪业造成巨大经济损失。本研究的目的是建立一个局部预算模型,以确定两种消除猪肺炎支原体方案的投资回收期和经济价值。从2004年到2017年记录了70个实施群体封闭或全群用药方案以消除猪肺炎支原体的种猪场的回顾性数据。使用结束数据来估计猪肺炎支原体阴性和阳性流程之间下游生产性能的差异。假设一个有5000头母猪的自繁自养场每年生产135,870头断奶仔猪和125,000头育肥猪,采用群体封闭方案实施消除猪肺炎支原体的总成本为112,100美元,用药方案的成本为185,700美元。在下游生产性能方面,观察到平均日增重(ADG)和死亡率存在统计学差异(p < 0.05),但饲料转化率无差异。产生最大效益的参数与平均日增重的提高、生长猪抗生素用药的节省以及饲料转化率的提高有关。消除猪肺炎支原体的效益为每个农场每年877,375美元,或每头上市猪7.00美元。考虑到成功概率为83%,群体封闭方案在1年后的估计项目价值为616,121美元,用药方案成功概率为58%时的项目价值为323,177美元。当群体封闭方案每头母猪成本为145.64美元,用药方案每头母猪成本为101.78美元时,项目价值达到盈亏平衡点。群体封闭方案在销售猪肺炎支原体阴性猪开始后2个月达到投资回收期,用药方案根据每个方案的成功概率调整后为7个月。这里描述的方案可以很容易地应用,成功率很高,并且表明所获得的效益大于项目失败的成本。即使农场仅在一年保持阴性,下游的经济效益也值得投资。这些信息可能有助于生产者和兽医在其猪群中进行猪肺炎支原体消除方案的决策过程。